help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2008-0293
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baird, J.-P.
Right arrow Articles by Grigg, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baird, J.-P.
Right arrow Articles by Grigg, L. A.
Endocrinology Vol. 150, No. 3 1202-1216
Copyright © 2009 by The Endocrine Society

Orexin-A Hyperphagia: Hindbrain Participation in Consummatory Feeding Responses

John-Paul Baird, Angela Choe, Jasmine L. Loveland, Janine Beck, Carrie E. Mahoney, Julia S. Lord and Lindsay A. Grigg

Department of Psychology and Neuroscience Program, Amherst College, Amherst, Massachusetts 01002

Address all correspondence and requests for reprints to: John-Paul Baird, Department of Psychology, Amherst College, Amherst, Massachusetts 01002. E-mail: jpbaird{at}amherst.edu.

Orexin-A (ORXA) is an orexigenic neuropeptide produced by the lateral hypothalamus that increases food intake when injected into the brain ventricles or forebrain nuclei. We used a licking microstructure analysis to evaluate hindbrain and forebrain ORXA effects in intact and hindbrain-lesioned rats, to identify the motivational and anatomical bases of ORXA hyperphagia. Intact rats with cannulas in the fourth brain ventricle (4V) received vehicle (artificial cerebrospinal fluid) or ORXA (0.1, 0.4, 1, or 10 nM) injections before 90 min access to 0.1 M sucrose. Meal size and frequency were increased in a double-dissociated manner by the 1 and 10 nM doses, respectively. In experiment 2, 4V 1 nM ORXA was applied to rats offered solutions varied in caloric and gustatory intensity (water and 0.1 and 1 M sucrose). ORXA increased meal frequency for all tastants. ORXA increased meal size only for 0.1 M sucrose, by prolonging the meal without affecting early ingestion rate or lick burst size, suggesting that 4V ORXA influenced inhibitory postingestive feedback rather than taste evaluation. In experiment 3, rats with cannulas in the third ventricle (3V) received dorsal medullary lesions centered on the area postrema (APX group) or sham procedures, and licking for water and 0.1 and 1 M sucrose was evaluated after 1 nM 3V ORXA/artificial cerebrospinal fluid injections. The 3V ORXA increased 0.1 M sucrose meal size and meal frequency for all tastants in the sham group, as observed after 4V ORXA in experiment 2. In the APX group, 3V ORXA injections influenced meal frequency, but they no longer increased meal size. However, the APX rats increased meal size for 0.1 M sucrose after food and water deprivation and after 3V angiotensin II injection. They also showed meal size suppression after 3V injection of the melanocortin-3/4 receptor agonist melanotan II (1 nM). These findings suggest that the area postrema and subjacent nucleus of the solitary tract are necessary for increases in consummatory (meal size) but not appetitive (meal frequency) responses to 3V ORXA. The meal size increases may be due to reduced postingestive feedback inhibition induced by ORXA delivered to either the hindbrain or forebrain ventricles.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2009 by The Endocrine Society